EMEA-001664-PIP02-15-M05 - paediatric investigation plan

erenumab

Key facts

• Invented name:
  Aimovig
• Active Substance:
  erenumab
• Therapeutic area:
  Neurology
• Decision number:
  P/0475/2021
• PIP number:
  EMEA-001664-PIP02-15-M05
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Prevention of migraine headaches
• Route(s) of administration:
  Subcutaneous use
• Contact for public enquiries:

  Novartis Europharm Limited

  Tel. [phone]; E-mail: [e-mail]

• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  03/12/2021

Decision

P/0475/2021 : EMA decision of 3 December 2021 on the acceptance of a modification of an agreed paediatric investigation plan for erenumab (Aimovig), (EMEA-001664-PIP02-15-M05)

AdoptedReference Number: EMA/627444/2021